Litcius/Paper detail

Secondary Malignancy Risk Following Proton vs. X-ray Treatment of Mediastinal Malignant Lymphoma: A Comparative Modeling Study of Thoracic Organ-Specific Cancer Risk

Laila König, P. Haering, Clemens Lang, M. Splinter, Bastian von Nettelbladt, Fabian Weykamp, Philipp Hoegen, Jonathan W. Lischalk, Klaus Herfarth, Jürgen Debus, Juliane Hörner‐Rieber

2020Frontiers in Oncology26 citationsDOIOpen Access PDF

Abstract

Purpose Proton radiotherapy (PRT) is potentially associated with a lower risk for secondary malignancies due to decreased integral dose to surrounding organs at risk (OARs). Prospective trials confirming this are lacking due to the need for long term follow-up and the ethical complexities of randomizing patients between modalities. The objective of the current study is to calculate the risk for secondary malignancies following PRT and photon-based intensity-modulated radiotherapy (IMRT). Materials and Methods Twenty-three patients (16 female, 7 male), previously treated with active scanning PRT for malignant mediastinal lymphoma at Heidelberg Ion Beam Therapy Center (HIT), were retrospectively re-planned using helical photon IMRT. The risk for radiation-induced secondary malignancies was estimated and evaluated using two distinct prediction models (Dasu et al., 2005; Mondlane et al., 2017; Schneider et al-, 2005; Schneider et al. 2005). Results According to the Dasu model, the median absolute total risk for tumor induction following IMRT was 4.4% (range 3.3-5.8%), 9.9% (range 2.0-27.6%), and 1.0% (range 0.5-1.5%) for lung, breast, and esophageal cancer. For PRT it was significantly lower for the aforementioned organs at 1.6% (range 0.7-2.1%), 4.5% (range 0.0-15.5), and 0.8% (range 0.0-1.6%), respectively (p≤0.01). The mortality risk from secondary malignancies was also significantly reduced for PRT relative to IMRT 1.1% vs. 3.1% (p<0.001), 0.9% vs. 1.9% (p<0.001) and 0.7% vs. 1.0% (p-<0.001) for lung, breast, and esophageal tumors, respectively. Using the Schneider model, a significant risk reduction of 54.4% (range 32.2-84.0%), 56.4% (range 16.0-99.4%), and 24.4% (range 0.0-99.0%) was seen for secondary lung, breast, and esophageal malignancies favoring PRT versus x-ray based IMRT (p≤0.01). Conclusion Based on two prediction models, PRT for malignant mediastinal lymphoma is expected to reduce the risk for radiation-induced secondary malignancies compared with the x-ray based IMRT. The young age and long natural history of patients diagnosed with mediastinal lymphoma predisposes them to a high risk of secondary malignancies following curative radiotherapy treatment, and as a consequence potentially reducing this risk by utilizing advanced radiation therapy techniques such as PRT should be considered.

Topics & Concepts

MedicineRadiation therapyProton therapyNuclear medicineMalignancyCancerMediastinumLymphomaInternal medicineRadiologyOncologyRadiation Therapy and DosimetryAdvanced Radiotherapy TechniquesLung Cancer Diagnosis and Treatment
Secondary Malignancy Risk Following Proton vs. X-ray Treatment of Mediastinal Malignant Lymphoma: A Comparative Modeling Study of Thoracic Organ-Specific Cancer Risk | Litcius